Active Hormone Therapy Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

How It Works

1. Share a Few Details — Enter your cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Hormone Therapy Clinical Trials FAQ

What hormone therapy trials are available for prostate cancer?

Prostate cancer hormone therapy trials are testing next-generation androgen receptor signaling inhibitors (ARSIs), combinations with PARP inhibitors for BRCA-mutated tumors, novel radioligand therapies (lutetium-177 PSMA), and strategies to overcome castration resistance. Many trials are available for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC).

Can breast cancer patients join hormone therapy clinical trials while on aromatase inhibitors?

Some trials add an investigational agent (like a CDK4/6 inhibitor, PI3K inhibitor, or immunotherapy) on top of an existing aromatase inhibitor. Others test new endocrine agents (like elacestrant or lasofoxifene) as a replacement for standard hormone therapy. Whether you can stay on your current therapy depends on the specific trial — Trialify's eligibility questionnaire surfaces these requirements clearly.

What is endocrine resistance, and are there trials for it?

Endocrine resistance (or hormone resistance) happens when a cancer that initially responded to hormone therapy stops responding. It's one of the most active areas of clinical research. For breast cancer, trials are testing agents that overcome ESR1 mutations (a common resistance mechanism). For prostate cancer, trials target multiple resistance mechanisms including AR splice variants. Your oncologist can order liquid biopsy testing to identify which resistance mechanism is driving your cancer.

What are the most common side effects in hormone therapy clinical trials?

Side effects of hormone therapy depend on the cancer type and specific agent. For prostate cancer (ADT): hot flashes, fatigue, sexual dysfunction, bone loss, and metabolic changes. For breast cancer (aromatase inhibitors): joint pain, hot flashes, bone thinning, and mood changes. Adding investigational agents can introduce additional side effects specific to the new drug — the trial team will monitor and support you through these.

Hormone Therapy Trials by Cancer Type

• Prostate Cancer — Prostate cancer trials are exploring next-generation hormone therapies, PARP inhibitors, radiopharmaceuticals, and novel immunotherapy combinations — including options for castration-resistant disease.
• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.
• Metastatic Prostate Cancer — Metastatic prostate cancer includes hormone-sensitive (mHSPC) and castration-resistant (mCRPC) stages. Trials are advancing PARP inhibitors (for HRR gene mutations), lutetium-177 PSMA radioligand therapy, novel AR inhibitors, and immunotherapy strategies across all metastatic disease settings.